Cargando…
Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria
Bacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224320/ https://www.ncbi.nlm.nih.gov/pubmed/34064302 http://dx.doi.org/10.3390/pharmaceutics13060773 |
_version_ | 1783711863301734400 |
---|---|
author | Roque-Borda, Cesar Augusto da Silva, Patricia Bento Rodrigues, Mosar Corrêa Azevedo, Ricardo Bentes Di Filippo, Leonardo Duarte, Jonatas L. Chorilli, Marlus Festozo Vicente, Eduardo Pavan, Fernando Rogério |
author_facet | Roque-Borda, Cesar Augusto da Silva, Patricia Bento Rodrigues, Mosar Corrêa Azevedo, Ricardo Bentes Di Filippo, Leonardo Duarte, Jonatas L. Chorilli, Marlus Festozo Vicente, Eduardo Pavan, Fernando Rogério |
author_sort | Roque-Borda, Cesar Augusto |
collection | PubMed |
description | Bacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developing much bacterial resistance. The rapid interaction between AMPs and the bacterial cell membrane means that the bacteria cannot easily develop resistance mechanisms. In addition, various drugs for clinical use have lost their effect as a conventional treatment; however, the synergistic effect of AMPs with these drugs would help to reactivate and enhance antimicrobial activity. Their efficiency against multi-resistant and extensively resistant bacteria has positioned them as promising molecules to replace or improve conventional drugs. In this review, we examined the importance of antimicrobial peptides and their successful activity against critical and high-priority bacteria published in the WHO list. |
format | Online Article Text |
id | pubmed-8224320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82243202021-06-25 Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria Roque-Borda, Cesar Augusto da Silva, Patricia Bento Rodrigues, Mosar Corrêa Azevedo, Ricardo Bentes Di Filippo, Leonardo Duarte, Jonatas L. Chorilli, Marlus Festozo Vicente, Eduardo Pavan, Fernando Rogério Pharmaceutics Review Bacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developing much bacterial resistance. The rapid interaction between AMPs and the bacterial cell membrane means that the bacteria cannot easily develop resistance mechanisms. In addition, various drugs for clinical use have lost their effect as a conventional treatment; however, the synergistic effect of AMPs with these drugs would help to reactivate and enhance antimicrobial activity. Their efficiency against multi-resistant and extensively resistant bacteria has positioned them as promising molecules to replace or improve conventional drugs. In this review, we examined the importance of antimicrobial peptides and their successful activity against critical and high-priority bacteria published in the WHO list. MDPI 2021-05-21 /pmc/articles/PMC8224320/ /pubmed/34064302 http://dx.doi.org/10.3390/pharmaceutics13060773 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Roque-Borda, Cesar Augusto da Silva, Patricia Bento Rodrigues, Mosar Corrêa Azevedo, Ricardo Bentes Di Filippo, Leonardo Duarte, Jonatas L. Chorilli, Marlus Festozo Vicente, Eduardo Pavan, Fernando Rogério Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria |
title | Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria |
title_full | Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria |
title_fullStr | Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria |
title_full_unstemmed | Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria |
title_short | Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria |
title_sort | challenge in the discovery of new drugs: antimicrobial peptides against who-list of critical and high-priority bacteria |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224320/ https://www.ncbi.nlm.nih.gov/pubmed/34064302 http://dx.doi.org/10.3390/pharmaceutics13060773 |
work_keys_str_mv | AT roquebordacesaraugusto challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria AT dasilvapatriciabento challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria AT rodriguesmosarcorrea challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria AT azevedoricardobentes challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria AT difilippoleonardo challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria AT duartejonatasl challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria AT chorillimarlus challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria AT festozovicenteeduardo challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria AT pavanfernandorogerio challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria |